GT Apeiron Announces Development Candidate Nomination of Brain Penetrant PRMT5 Inhibitor, GTA182, for the Potential Treatment of MTAP-Deleted Solid Cancers GT Apeiron Therapeutics announces development candidate nomination of GTA182, a brain penetrant MTA-cooperative PRMT5 inhibitor